Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
FR177391 is promising treatment option for management of hypertriglyceridemia
December 29th, 2005
FR177391 is a promising treatment option for the management of hypertriglyceridemia. According to a study from Japan, "The pharmacological effect of FR177391, isolated from Serratia liquefaciens No. 1821, was studied in normal animals and various types of animal models of hypertriglyceridemia." M. Inami and colleagues working with Astellas Pharma determined, "Treatment of normal mice with FR177391 resulted in an increase in heparin-releasable lipoprotein lipase (LPL) activity in the blood and epididymal fat tissue. FR177391 treatment decreased triglyceride (TG) and increased high-density lipoprotein cholesterol in the blood in normal rats...
Source: Blood Weekly (2005-12-29)
|
